Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Extracellular Vesicles (EVs) & Nanoparticles 2024: Diagnostics, Delivery, Therapeutics

Extracellular Vesicles (EVs) & Nanoparticles 2024: Diagnostics, Delivery, Therapeutics Agenda



Co-Located Conference Agendas

Extracellular Vesicles (EVs) & Nanoparticles 2024: Diagnostics, Delivery, Therapeutics | The Space Summit 2024 | 

Print Agenda

Wednesday, 3 April 2024

08:00

Conference Registration and Materials Pick-Up + Coffee-Pastries in the Exhibit Hall

08:30

Mei HeConference Chair

Welcome and Introduction by Conference Chairperson
Mei He, Associate Professor, University of Florida, United States of America

08:45

Michael GranerConference Chair

Welcome and Introduction to the Conference by Conference Co-Chairperson
Michael Graner, Professor, Dept of Neurosurgery, University of Colorado Anschutz School of Medicine, United States of America


Session Title: Conference Opening Session - Extracellular Vesicles 2024

09:00

Danilo TagleKeynote Presentation

Opening Keynote Presentation: NCATS Efforts in Catalyzing EV Research
Danilo Tagle, Director, Office of Special Initiatives, National Center for Advancing Translational Sciences at the NIH (NCATS), United States of America

09:30

Dominique PV de KleijnKeynote Presentation

Plasma Extracellular Vesicles for Cardiovascular Disease
Dominique PV de Kleijn, Professor Experimental Vascular Surgery, Professor Netherlands Heart Institute, University Medical Center Utrecht, The Netherlands, Netherlands

Cardiovascular Disease (CVD) is with the cardiovascular events of Ischemic Heart Disease and Stroke, the number 1 and 2 cause of death in the world and expect to increase especially in Asia. Ischemic heart disease (IHD) comprises 2 entities: Chronic Coronary Syndrome (CCS) and Acute Coronary Syndrome (ACS). Because CCS is associated with 6-8 times increased risk of adverse cardiovascular events like myocardial infarction and death, early recognition of CCS. Blood markers for CCS do not exist, resulting in that 80-90% of chest pain patients undergoing costly imaging do not have CCS. We use plasma extracellular vesicle protein content of vesicles from plasma subfractions as an accurate source for early diagnosis of CCS better than a clinical risk model. Using automated plasma EV fraction analysis and CD9 as an internal marker, we hope with the plasma EV test to reduce the numbers of patients without CCS that are referred for costly imaging.

10:00

Steven SticeKeynote Presentation

Moving Neural Stem Cell Derived Exosome into Clinical Trials: Manufacturing and Mechanistic Considerations
Steven Stice, Co-Founder and Chief Scientific Officer, Aruna Bio; DW Brook Distinguished Professor and Director of the Regenerative Bioscience Center, Georgia Research Alliance Eminent Scholar, University of Georgia, United States of America

Neural stem cell EVs (NSC EVs) derived in bioreactors have therapeutic potential for treating neurological disease and acute ischemic stroke (AIS). New FDA Investigational New Drug (IND) applications are being filed and specifically, we have an open IND for AIS. As the field grows, new INDs will be filed for various other therapeutic indications. In order for EV therapeutics to move efficiently through the regulatory process to approval, there is a need for more emphasis on and development of analytical assays directly related to complex, and likely multimodal, mechanisms of action. Research focused on this area will lead to new disease-specific potency assays and identification of critical quality attributes. Beyond AIS, one of the most promising applications of NSC EVs is in the treatment of amyotrophic lateral sclerosis (ALS). ALS is a neurodegenerative disease that affects the motor neurons in the brain and spinal cord. In a preliminary study, we have shown that NSC EVs significantly preserved motor function, decreased serum neurofilament light chain, and prolonged survival in ALS mice. NSC EVs also reduced inflammatory mediators TNFa, IL-1ß, IL-6, RIPK1, and NLRP3 in the lumbar spinal. These results suggest that NSC EVs have the potential to be developed as a therapeutic for ALS. The complex pathogenesis in the central nervous system during ALS suggests the need to develop drugs with multimodal therapeutic action and will likely require the development of multiple potency assays relevant to the active agents in and on the surface of the NSC EVs.

10:30

Title to be Confirmed.
Marcin Jurga, Chief Scientific Officer, EXO Biologics SA, Belgium

11:00

Mid-Morning Coffee Break and Networking in the Exhibit Hall

11:30

Daniel ChiuKeynote Presentation

High-Resolution Analysis of Single Extracellular Vesicles and Particles with Digital Flow Cytometry and Super-Resolution Imaging
Daniel Chiu, A. Bruce Montgomery Professor of Chemistry, University of Washington, United States of America

We have developed a multi-parametric high-throughput flow-based method for the analysis of individual extracelluar vesicles and particles (EVPs), and a super-resolution method for sizing individual EVPs in a high-throughput fashion. EVPs are highly heterogeneous and comprise a diverse set of surface protein markers as well as intra-vesicular cargoes. Yet, current approaches to the study of EVPs lack the necessary sensitivity and precision to fully characterize and understand the make-up and the distribution of various EV subpopulations that may be present. Digital flow cytometry (dFC) provides single-fluorophore sensitivity and enables multiparameter characterization of EVPs, including sin­gle-EVP phenotyping, the absolute quantitation of EVP concentrations, and biomarker copy numbers. dFC has a broad range of applications, from analysis of single EVPs such as exosomes or RNA-binding proteins to characterization of therapeutic lipid nano­particles, viruses, and proteins. dFC also provides absolute quantita­tion of non-EVP samples such as dyes, beads, and Ab-dye conjugates.

12:00

Particle Metrix Technology Spotlight Presentation

12:30

Networking Lunch in the Exhibit Hall + Poster Viewing


Session Title: Extracellular Vesicles for Drug Delivery and Therapeutics Applications

13:30

Large Scale Manufacturing, Cargo Profiling, and Functional Effects of hTERT MSC EVs
Heather Branscome, Senior Scientist, ATCC and Research Assistant, George Mason University, United States of America

Ocular diseases are a major cause of visual impairment and morbidity. Furthermore, exposure to ionizing radiation (IR) can cause direct damage to the eye. Therefore, there is an urgent need to explore novel ocular therapeutics. Extracellular Vesicles (EVs) from Mesenchymal Stem Cells (MSCs) have demonstrated widespread regenerative properties across multiple pathologies. However, the reparative effects of MSC EVs against ocular damage remains relatively unexplored. Here, we report a large-scale platform for manufacturing of EVs from hTERT-immortalized MSCs and evaluate their reparative properties on retinal cells before and after exposure to IR. Additionally, we evaluate the efficacy of a novel EV lyophilization buffer for improved EV storage, transport, and stability. Physical and biochemical properties of EVs were assayed using various techniques including NTA, western blot, mass spectrometry, RNAseq, and multiplex immunoassays. EV functionality was evaluated in vitro using a combination of assays to assess cell viability, cell migration, cell cycle, and apoptosis before and after exposure to IR. Collectively, our data suggests that hTERT MSC EVs are enriched with unique cargos and that these EVs exert reparative properties on retinal cells in vitro against irradiation-induced damage. Importantly, lyophilization of EVs further extended their shelf life without impacting their function.

14:00

Damien PearseKeynote Presentation

Therapeutic Development and Use of Exosomes in Neurological Disease and Injury
Damien Pearse, Professor, Department of Neurological Surgery; The John M. and Jocelyn H.K. Watkins Distinguished Chair in Cell Therapies, University of Miami Miller School of Medicine, United States of America

Exosomal vesicles (EVs) derived from neural and non-neural sources have shown potential in limiting damage to the CNS as well as promoting neurorepair. Our laboratory is interested in the development and utility of glial cell-derived exosomes as therapeutic agents in models of spinal cord injury, multiple sclerosis, and amyotrophic lateral sclerosis, among other neurological conditions. Herein I will discuss our advances in characterizing EVs from different cell sources, examining their ability to alter cellular responses in vitro in neural cell assays as well as investigating their capacity to alter pathological processes in neurological injury and disease paradigms in rodents with the goal of moving this approach towards clinical evaluation in humans.

14:30

Utility and Application of Single and Bulk EV Analysis in Pediatric Neuroimmune Disorders
Setty Magaña, Assistant Professor of Neurology & Pediatrics, Nationwide Children's Hospital, The Ohio State University, United States of America

Childhood acquired demyelinating syndromes (ADS) of the central nervous system (CNS) represent a spectrum of monophasic or recurrent inflammatory diseases. The incidence of ADS ranges from 06. To 1.66 per 100,000 children.  Neurologic symptoms resulting from active neuro-inflammation can range from mild sensory symptoms to coma and death. Distinguishing amongst the clinically overlapping but prognostically distinct ADS is challenging due to lack of readily available and robust disease-specific biomarkers—underscoring a tremendous unmet clinical and research need. The most common childhood ADS is multiple sclerosis.  Pediatric-onset multiple sclerosis (POMS) represents 3-10% of all MS cases. The cause is unknown, however there is a complex interplay between genetics and environmental factors.  The patho-mechanisms leading to inflammatory demyelinating CNS lesions appears similar in adult and POMS, however POMS patients have a more inflammatory course at disease onset, higher relapse rate, more cognitive impairment and prominent contrast-enhancing lesions which represent blood-brain-barrier breakdown. In this presentation, I will review our work on establishing an EV-omics pipeline for biomarker discovery and pathomechanistic insights into pediatric acquired demyelinating syndromes.

15:00

Engineering EVs for Cardiovascular Diseases
Eun Ji Chung, Dr. Karl Jacob Jr. and Karl Jacob III Early Career Chair, Associate Professor of Biomedical Engineering, Chemical Engineering and Materials Science, Surgery, and Medicine, University of Southern California, United States of America

Extracellular vesicles derived from healthy sources contain natural homing properties and therapeutic cargo and can be leveraged as biomimetic carriers for targeted delivery. Additionally, extracellular vesicles represent an endogenous source of nanoparticles and can offer enhanced safety as a nanoparticle platform technology. In this presentation, EVs derived from healthy cells of the vasculature and their ability to be engineered as agents that inhibit vascular calcification and inflammation in atherosclerosis will be included. Strategies to enable EV surface modification and enhance cargo loading will be presented, and the potential of engineered EVs towards clinical applications will be discussed.

15:30

Mid-Afternoon Coffee Break and Networking in the Exhibit Hall

16:00

Steve SoperKeynote Presentation

Determining Critical Quality Attributes (CQAs) of Adeno-Associated Virus Gene Therapies using Resistive Pulse Sensing
Steve Soper, Foundation Distinguished Professor, Director, Center of BioModular Multi-Scale System for Precision Medicine, The University of Kansas, United States of America

Adeno-associated virus (AAV) vectors have been used to successfully introduce therapeutic gene fragments (i.e., gene therapy) into host cells and thus offer a significant tool for combating diseases that are unaffected by conventional drug therapy. This has led to a significant number of new clinical trials involving AAVs. However, broad application of AAV gene therapy across potential disease targets is hampered by a lack in definition of critical quality attributes (CQAs), analytics to measure CQAs, development of universal customizable vector cassettes, and affordable manufacturing methods. Presently, one of the most significant production and quality control issues facing AAV manufacturing is the presence of non-transducing viral particles (including empty particles) in the final vector preparation. Not only does this introduce errors and inconsistencies in the identification of actual titer delivered to the patient, but it also results in decreased infectivity of the dose due to increased host immune response to the defective virions. The issue of empty capsids is considered one of the top five major concerns in the production of AAVs today. The establishment of quantifiable traits at various points in the production process along with suitable analytical techniques are needed. Techniques to determine the full-to-empty capsid ratio include transmission electron microscopy (TEM) and analytical ultracentrifugation. Unfortunately, these techniques are fraught with challenges. There have also been a number of different chromatographic techniques to determine the full-to-empty ratio, but are challenged by inter-laboratory variability. All of the aforementioned techniques are batch-type processes and thus, cannot do real-time reporting to optimize the manufacturing process in-line. In this presentation, we will discuss the use of synthetic nanopore-based sensors capable of detecting and characterizing AAVs. Specifically, we will discuss the use of nanopore technology to detect capsids, characterize capsids as either full or empty, and to analyze capsids to determine if they contain full-length or foreshortened gene fragments. The sensors consist of dual in-plane nanopores that flank either end of a nano-column from which one can deduce the electrophoretic mobility of the target nanoparticle. We will show that empty and full capsids possess different mobilities and with the use of resistive pulse sensing (RPS) and machine learning, we can classify the particles as either full or empty quantitatively in near real-time.

16:30

NanoFCM Technology Spotlight Presentation

17:00

Raymond SchiffelersKeynote Presentation

Nucleic Acid Delivery with Biological and Synthetic Lipid Nanoparticles
Raymond Schiffelers, Professor of Nanomedicine, University Medical Center Utrecht, Netherlands

Nucleic acid nanomedicines gain momentum. Starting with Onpattro, delivering siRNA to the liver and followed by the local injection of COVID mRNA vaccines, we currently witness an avalanche of new therapeutic applications. Following the same lipid nanoparticle recipe as Onpattro and the vaccines, enzyme replacement therapy for rare metabolic disorders in the liver and CRISPR mRNA/sgRNA combinations for hepatic gene editing are being explored clinically, amongst many others. For other applications in new tissues, this recipe needs to be tweaked. In this lecture, applications to spleen targeting, heart delivery and immune cell targeting will be discussed, and biological and synthetic systems are compared.

17:30

Networking Beer and Wine Reception - View Posters, Meet Exhibitors, View Exhibitor Demos, Network with Colleagues

19:00

Close of Day 1 of the Conference

Thursday, 4 April 2024

08:00

Morning Coffee, Pastries and Networking in the Exhibit Hall

08:30

Discovering the Secrets of Extracellular Vesicles for Diagnostics and Therapeutics
Fei Liu, Faculty of Medicine, Brigham and Women's Hospital, United States of America

Extracellular vesicles (EVs), particularly exosomes, play a crucial role in cell-to-cell communication by facilitating the exchange of biological information and materials. EVs are abundantly found in various clinical samples, including blood, urine, saliva, tears, and cerebrospinal fluid. Due to their cargo of diverse biomolecules such as proteins, peptides, lipids, and nucleic acids derived from parent cells, EVs hold great potential as valuable biomarkers for clinical diagnosis and prognosis. In this presentation, I will discuss our research findings on EV isolation techniques, biomarker discovery strategies, detection methods, and translational applications. Firstly, I will introduce the Exosome Total Isolation Chip (EXOTIC) device developed for isolating and identifying EVs from lung cancer patients. This platform enables modular separation and analysis of EV subtypes secreted by different cells along with their respective size distribution. Additionally, I will present the Exosome Detection via the Ultrafast-isolation System (EXODUS) for various applications including characterizing EVs in different biological samples and tracing tissue and cell functions based on urine samples. Next, I plan to introduce iTEARS, which is used to discover the secrets of tear EVs as biomarkers for detecting ocular disorders and systemic diseases. Furthermore, iNEBULA will be discussed for investigating the biological profiles of tear EV subsets with different sizes from healthy individuals and exploring the origins of EV proteins. Finally, I will present the gold nano-dual probe technique (nPES) for quantitative detection of individual plasma exosomes from patients with pancreatic cancer. Simultaneously, a robust acute pancreatitis identification and diagnosis (RAPIDx) method will be demonstrated through proteomic fingerprinting analysis of intact nanoscale EVs from clinical samples. The goal of our work on EVs is to support fundamental research, promote clinical diagnosis, and facilitate the translation of therapeutics.

09:00

Shilpa BuchKeynote Presentation

HIV and Opioid-Mediated Aging and Cognitive Decline: Implications for Astrocyte EVs
Shilpa Buch, Professor and Senior Executive Vice Chair for Research, University of Nebraska Medical Center, United States of America

Although cART usage has increased the lifespan of HIV+ individuals, paradoxically, its dependence is also associated with increased risk of comorbidity of HIV-Associated Neurocognitive Disorders (HAND). Heroin abuse can accelerate the process of HAND pathogenesis, specifically age-sensitive brain functional networks in patients. Based on our previous findings that astrocytes play a major role in HIV Tat & Morphine-mediated amyloidosis & senescence-like phenotype, and since these senescence associated secretory phenotype (SASP) cargoes can be released in extracellular vesicles (EVs), we sought to assess whether HIV Tat protein and morphine-stimulated astrocyte derived EVs (ADEVs) containing these toxic cargoes could induce synaptodegeneration in neurons invitro and when administered in the brains of naïve mice. This study aims to focus on the cellular cross-talk mediated by ADEVs in inducing synaptodendritic injury. Methods: We assessed the novel role of long noncoding (lnc) RNA BACE1 antisense (AS) in HIV-Tat/morphine mediated astrocytic senescence and amyloidosis and in mediating neuronal injury. Additionally, we assessed the behavioral deficits as well as ageing phenotype in morphine dependent, as well as Tat-ADEV injected mice. Results: Both HIV-Tat and Morphine-induced senescence phenotype (p16, p21, ROS, cell cycle arrest, ß- gal activity, cytokines) and accumulation of amyloids in human astrocytes in culture. Furthermore, using gene silencing approach, we showed that this phenomenon was regulated by lncRNA BACE1AS. Next, EVs isolated from HIV-Tat or morphine exposed human astrocytes were demonstrated to shuttle the SASP cargoes and also that, the EV numbers were regulated by lncRNA BACE1AS. These EVs upon being uptaken by the neurons both in vitro and in vivo, were shown to induce neuronal senescence & synaptodendritic injury. Interestingly, validation in vivo demonstrated that morphine administered mice exhibited ageing phenotype in the frontal cortex and hippocampus and this was associated with cognitive decline. There was also synaptodegeneration in the hippocampi of mice injected with  these ADEVs. Conclusion(s): This study underscores the role of lncRNA BACE1AS in astrocytic senescence and amyloidosis and the role of ADEVs in mediating synaptodegeneration leading to cognitive impairments associated with HAND.

09:30

EXODUS BIOHigh-Efficiency Isolation of Exosomes and Its Application in Diagnosis and Treatment
Johnny Zhuang, Product Application Scientist, EXODUS BIO

Introducing EXODUS, our innovative automatic exosome isolation system, which employs advanced techniques such as periodic negative pressure oscillation and double-coupled harmonic oscillation. This unique integration ensures the high yield and purity of label-free exosomes. Widely utilized in research for disease biomarker discovery, EXODUS also offers a large-scale model, the EXODUS-T, specifically designed to cater to industrial production demands.

10:00

Beckman Coulter Life SciencesFlexible Solutions for Extracellular Vesicle Analysis
Jason Lowery, Regional Marketing Development Manager, Beckman Coulter Life Sciences

During this presentation, we will discuss some of the current challenges with Flow Cytometry for Extracellular Vesicle (EV) analysis and what it would take to make a purpose-built analyzer. With over 88 years of experience, Beckman Coulter Life Sciences is dedicated to driving innovation in research through improvements in EV analysis. We offer a number of products and solutions, including the CytoFLEX Flow Cytometer and the CytoFLEX SRT benchtop cell sorter, providing the sensitivity and performance you need in an easy-to-use system, for your EV research solutions.

10:30

Mid-Morning Coffee Break and Networking in the Exhibit Hall

11:00

Aethlon Medical Technology Spotlight Presentation

11:30

Tony Jun HuangKeynote Presentation

Acoustofluidics: Merging Acoustics and Fluid Mechanics for Biomedical Applications
Tony Jun Huang, William Bevan Distinguished Professor of Mechanical Engineering and Materials Science, Duke University, United States of America

The use of sound has a long history in medicine. Dating back to 350 BC, the ancient Greek physician Hippocrates, regarded as “the father of medicine”, devised a diagnostic method for detecting fluid in the lungs by shaking patients by their shoulders and listening to the resulting sounds emanating from their chest. As acoustic technology has advanced, so too has our ability to “listen” to the body and better understand underlying pathologies.  The 18th century invention of the stethoscope allowed doctors to gauge the health of the heart; the 20th century invention of ultrasound imaging revolutionized the field of biomedical imaging and enabled doctors to diagnose a range of conditions in the fields of obstetrics, emergency medicine, cardiology, and pulmonology. In the last decade, a new frontier in biomedical acoustic technologies has emerged, termed acoustofluidics, which joins cutting-edge innovations in acoustics with micro- and nano- scale fluid mechanics. Advances in acoustofluidics have enabled unprecedented abilities in the early detection of cancer, the non-invasive monitoring of prenatal health, the diagnoses of traumatic brain injury and neurodegenerative diseases, and have also been applied to develop improved therapeutic approaches for transfusions and immunotherapies. In this talk, I summarize our lab’s recent progress in this exciting field and highlight the versatility of acoustofluidic tools for biomedical applications through many unique examples, ranging from the development of high-purity, high-yield methods for the separation of circulating biomarkers such as exosomes and circulating tumor cells, to highly precise, biocompatible platforms for manipulating cells and studying cell-cell communication, to strategies for high-resolution 3D bioprinting. These acoustofluidic devices can precisely manipulate objects across 7 orders of magnitude (from a few nanometers to a few centimeters). Thanks to these favorable attributes (e.g., versatility, precision, and biocompatibility), acoustofluidic devices harbor enormous potential in becoming a leading technology for a broad range of applications, playing a critical role for translating innovations in technology into advances in biology and medicine.

12:00

Delivery of Mitochondria-Containing Extracellular Vesicles to the BBB
Devika Manickam, Associate Professor, Duquesne University, United States of America

Extracellular vesicles (EVs) are natural, cell-secreted nanoparticles that have known roles in intercellular communication. Our work has demonstrated that the innate mitochondrial cargo in EVs can be transferred to recipient cells and tissues resulting in increased mitochondrial function. My talk will describe how delivery of innate mitochondrial cargo can be exploited for BBB protection in ischemic stroke.

12:30

Title to be Confirmed.
Sukhbir Kaur, Staff Scientist, National Cancer Institute, National Institutes of Health, United States of America

13:00

Networking Buffet Lunch in the Exhibit Hall -- Networking with Colleagues, Engage with Exhibitors and View Posters

14:00

Round-Table Open Discussion: How does a Scientist Send Their Experiment into Space On-Board International Space Station ? -- Q&A with Mike Roberts and Kristin Kopperud, ISS-National Laboratory

15:00

Mid-Afternoon Coffee Break and Networking in the Exhibit Hall


Session Title: The Convergence of Virus Research and EV Research


Session Chairperson: Professor Michael Graner

15:30

Andrea RaymondKeynote Presentation

Title to be Confirmed.
Andrea Raymond, Associate Professor, Herbert Wertheim College of Medicine, Florida International University, United States of America

16:00

Exploiting an Antiviral Response to Improve Drug Delivery
Tom Anchordoquy, Professor, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, United States of America

Early studies in gene delivery observed a period of time (days to weeks) after an initial injection when a repeat injection of lipoplexes had a minimal effect on expression.  This “refractory period” was originally attributed to viral promoters and CpG sequence that elicit the production of inflammatory cytokines which silence expression.  However, subsequent studies with plasmids lacking these components still observed a refractory period.  Ultimately, this effect is responsible for the inability to use repeat administration to achieve progressively greater levels of gene expression and obtain therapeutic efficacy.  While relatively few studies have characterized delivery after repeat injection, our recent experiments have shown that the refractory response involves the inhibition of particle uptake in addition to the silencing of gene expression.  Although this results in reduced delivery to normal tissues that respond to cytokines, the immunosuppressed state of established tumors allows unimpeded delivery upon subsequent injections.  Our data suggest that this effect can be exploited to reduce off-target accumulation and improve delivery to the tumor during repeat injection.

16:30

Extracellular Condensates (ECs) are Endogenous Modulators of HIV Transcription and Latency Reactivation
Chioma Okeoma, Professor & Vice Chair of Research, New York Medical College, United States of America

Persistence of latent HIV reservoir is the key challenge to HIV cure because the latent reservoir is not eliminated by ART and they serve as sources for viral rebound upon cessation of ART. Mechanisms that regulate HIV persistence are still unclear but emerging data highlight a possible role by extracellular condensates (ECs). In this study, we used model systems of post-integration latency to explore the role of ECs in reprogramming latent cells. We found that ECs from the brain of uninfected macaques (VEH) and SIV infected macaques (VEH|SIV) activate HIV transcription and that VEH and VEH|SIV ECs significantly increased expression of HIV antigen in latently infected cells. But the activation of HIV transcription, antigen expression, and latency reactivation was inhibited by ECs from the brain of THC-treated SIV infected macaques (THC|SIV). The virus produced by EC-reactivated latently infected cells potently infected other cells through cell-free and cell-cell mechanisms. The VEH|SIV ECs reversed dexamethasone-mediated inhibition of HIV transcription while TNFa-mediated reactivation of latency was reversed by THC|SIV. Transcriptome analysis showed substantial levels of altered host gene regulation, while Secretome analysis of HIV latently infected cells revealed that THC|SIV ECs increased secretion of Th2 cytokines and decreased secretion of proinflammatory cytokines. Overall, our findings support the hypothesis that ECs are endogenous host factors that regulate HIV persistence and provide evidence of the potential utility of THC ECs as useful latency promoting agents.

17:00

Targeting Viral Genomic RNA by the Delivery of Extracellular Vesicles-Mediated CRISPR Machinery
Houjian Cai, Associate Professor, University of Georgia, United States of America

Extracellular vesicles (EVs) have recently been co-opted as vehicles for the delivery of therapeutics, including CRISPR-Cas9 (Cas9), and are now being modified for higher gene editing efficiency. N-myristoylation is known to translocate Src kinase to the membrane. We reasoned that fusion of the N-terminal of Src to Cas9 may increase localization with the membrane, and subsequently increase EV-loading and gene editing efficacy in EV-treated recipient cells. Our study demonstrate that fusion of the octapeptide to Cas9 induced N-myristoylation and encapsulation of the mCas9/sgRNA complex into EVs. We provide proof of concept for N-myristoylation as a method to increase EV-mediated delivery of therapeutics. The technology can be applied for targeting oncogenic genes in prostate cancer cells.

17:30

Extracellular Vesicle Isolation Methods Identify Distinct HIV-1 Particles Released from Chronically Infected T-cells
Fatah Kashanchi, Professor and Director of Research, Lab of Molecular Virology, George Mason University, United States of America

In 2022, 1.5 million people acquired Human Immunodeficiency Virus (HIV-1), and an estimated 37.7 million individuals lived with HIV-1 (PLWH) worldwide. While combination antiretroviral therapy suppresses viral replication, it does not silence viral transcription. We have identified presence of HIV-1 products, including non-coding viral RNA and proteins, within extracellular vesicles (EVs). These EVs are not infectious and can be isolated from cell culture supernatants of HIV-1 chronically infected cell lines and biofluids. Here we expanded upon a sequential differential ultracentrifugation (DUC) method by employing higher g-force with longer spin times to recover smaller EVPs (<100 nm) and have found presence of virus in both large and very small EVPs. Furthermore, we modified a virus recovery assay which indicates that these EVPs were infectious, including the novel EVPs under 100 nm. Standard assays for EV characterizations were used for validation.  Data was further validated using filtrations and other methods of EV purification. Viral and EV markers were used to quantify each prep. Collectively, we identified unique, infectious particles smaller than the currently accepted size for HIV-1. This methodology may be employed for other viruses or infectious agents where EVPs may impact disease progression by transmitting highly replicating virulent nucleic acids.

18:00

Round-Table Discussion on Viruses and EVs Moderated by Professor Michael Graner

18:30

Close of Conference


Add to Calendar ▼2024-04-03 00:00:002024-04-04 00:00:00Europe/LondonExtracellular Vesicles (EVs) and Nanoparticles 2024: Diagnostics, Delivery, TherapeuticsExtracellular Vesicles (EVs) and Nanoparticles 2024: Diagnostics, Delivery, Therapeutics in Miami, FloridaMiami, FloridaSELECTBIOenquiries@selectbiosciences.com